Effect of aggressively driven intravenous iron therapy on infectious complications in end-stage renal disease patients on maintenance hemodialysis

American Journal of Therapeutics

Volumn 21, Issue 4, 2014, Pages 250-253

  Bansal, Anip ^a   Sandhu, Gagangeet ^a   Gupta, Isha ^a   Kalahalli, Shriharsha ^a   Nayak, Rushi ^a   Zouain, Eduardo ^a   Chitale, Rohit A ^b   Meisels, Ira ^a   Chan, Germaine ^a  

^a Division of Nephrology St Luke's Roosevelt Hospital Center Columbia University College of Physicians and Surg ^*  (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

anemia; end stage renal disease patients; infectious complications; intravenous iron therapy

Indexed keywords

FERRITIN; IRON SACCHARATE; TRANSFERRIN; ANTIANEMIC AGENT; IRON;

ADULT; AGED; ANEMIA; ARTICLE; BACTEREMIA; DRUG EFFECT; END STAGE RENAL DISEASE; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HUMAN; INCIDENCE; INFECTION RISK; INFECTIOUS COMPLICATION; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; OSTEOMYELITIS; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOFT TISSUE INFECTION; TREATMENT OUTCOME; ANEMIA, IRON-DEFICIENCY; BACTERIAL INFECTIONS; BLOOD; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADMINISTRATION, INTRAVENOUS; AGED; ANEMIA, IRON-DEFICIENCY; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERRITINS; HEMATINICS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 84904256446     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31825425bd     Document Type: Article

References (10)

1. Solomon SD, Uno H, Lewis EF, et al. Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010; 363:1146-1155.
2. Nissenson AR, Lindsay RM, Swan S, et al. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am J Kidney Dis. 1999;3:471-482. (Pubitemid 29107024)
3. Aronoff GR, Bennett WM, Blumenthal S, et al. United States Iron Sucrose (Venofer) Clinical Trials Group. Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens. Kidney Int. 2004;66:1193-1198.
4. Coyne DW, Kapoian T, Suki W, et al; DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975-984. (Pubitemid 46434515)
5. Kapoian T, OMara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19:372-379. (Pubitemid 351240658)
6. Boelaert J, Daneels R, Schurgers M, et al. Iron overload in hemodialysis patients increases the risk of bacteremia: A prospective study.Nephrol Dial Transplant. 1990;5:130-134.
7. Hoen B, Paul-Dauphin A, Hestin D, et al. Epibacdial: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol. 1998;9:869-876.
8. Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol. 2002;57:457-461. (Pubitemid 34625055)
9. Brewster UC, Coca SG, Reilly RF, et al. Effect of intravenous iron on hemodialysis catheter microbial colonization and blood-borne infection. Nephrology (Carlton). 2005;10:124-128. (Pubitemid 40776270)
10. Sirken G, Raja R, Rizkala AR. Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients. Clin Nephrol. 2006;66: 348-356. (Pubitemid 44718146)